Advanced glycation endproducts in diabetes-related macrovascular complications: focus on methylglyoxal.

Casper G Schalkwijk, Linda Renata Micali, Kristiaan Wouters

Journal: Trends in endocrinology and metabolism: TEM 2022;34(1):49-60

PMID: 36446668

Full Text on Elsevier Science View on PubMed

Abstract

Diabetes is associated with vascular injury and the onset of macrovascular complications. Advanced glycation endproducts (AGEs) and the AGE precursor methylglyoxal (MGO) have been identified as key players in establishing the relationship between diabetes and vascular injury. While most research has focused on the link between AGEs and vascular injury, less is known about the effects of MGO on vasculature. In this review, we focus on the mechanisms linking AGEs and MGO to the development of atherosclerosis. AGEs and MGO are involved in many stages of atherosclerosis progression. However, more research is needed to determine the exact mechanisms underlying these effects. Nevertheless, AGEs and MGO could represent valid therapeutic targets for the macrovascular complications of diabetes.

Address: Department of Internal Medicine, CARIM School for Cardiovascular Diseases, MUMC+, Maastricht, The Netherlands.; Karolinska Institutet, Stockholm, Sweden.; Department of Internal Medicine, CARIM School for Cardiovascular Diseases, MUMC+, Maastricht, The Netherlands. Electronic address: [email protected].

DOI: 10.1016/j.tem.2022.11.004

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetes.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Glycation End Products, Advanced, Pyruvaldehyde, Vascular System Injuries, Magnesium Oxide, Diabetes Mellitus, Atherosclerosis